Yazar "Gülmez, Ahmet" için listeleme
-
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group
Erol, Cihan; Şendur, Mehmet Ali Nahit; Bilgetekin, İrem; Bayır Garbioğlu, Duygu; Hamdard, Jamshid; Akbaş, Sinem; Hizal, Mutlu; Arslan, Çağatay; Sevinç, Alper; Küçükarda, Ahmet; Erdem, Dilek; Kahraman, Seda; Çakır, Emre; Demirkıran, Aykut; On, Sercan; Doğan, İzzet; Erdoğan, Atike Pınar; Koca, Sinan; Kubilay, Pınar; Eren, Orhan Önder; Çılbır, Ebru; Çelik, Emir; Araz, Murat; Tataroğlu Özyükseler, Deniz; Yıldırım, Mahmut Emre; Bahçeci, Aykut; Taşkaynatan, Halil; Oyman, Abdilkerim; Deniz, Gülhan İpek; Menekşe, Serkan; Kut, Engin; Gülmez, Ahmet; Sakin, Abdullah; Nayır, Erdinç; Acar, Ramazan; Şen, Erdem; İnal, Ali; Turhal, Serdar; Kaya, Ali Osman; Paydaş, Semra; Taştekin, Didem; Hacıbekiroğlu, İlhan; Çinçin, İrfan; Bilici, Ahmet; Mandel, Nil Molinas; Şener Dede, Didem; Akıncı, Muhammed Bülent; Öksüzoğlu, Berna; Uncu, Doğan; Yalçın, Bülent; Artaç, Mehmet (NLM (Medline), 2022)Aims: The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) previously treated with oxaliplatin. We ... -
Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey
Hacıoğlu, Muhammet Bekir; Köstek, Osman; Karabulut, Senem; Taştekin, Didem; Sezgin Göksu, Sema; Alandağ, Celal; Akagündüz, Baran; Bilgetekin, İrem; Caner, Burcu; Şahin, Ahmet Bilgehan; Yıldız, Birol; Köse, Fatih; Kaplan, Muhammet Ali; Gülmez, Ahmet; Doğan, Ender; Güven, Deniz Can; Gürbüz, Mustafa; Ergun, Yakup; Karaağaç, Mustafa; Demiray, Atike Gökçen; Türker, Sema; Sakalar, Teoman; Özkul, Özlem; Akın Telli, Tuğba; Şahin, Süleyman; Kılıçkap, Saadettin; Bilici, Ahmet; Erdoğan, Bülent; Çiçin, İrfan (Imprimatur Publication, 2020)Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of ... -
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: A Turkish Oncology Group Study
Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Açıkgöz, Özgür; Sezer, Ahmet; Gürbüz, Mustafa; Ak, Naziye; Yücel, Şebnem; Ayhan, Murat; Erol, Cihan; Demirkıran, Aykut; Mandel, Nil Molinas; Shbair, Abdallah; Gökmen, İvo; Başoğlu, Tuğba; Paydaş, Semra; Demiray, Atike Gökçen; İriağaç, Yakup; Şakalar, Teoman; Zeynelgil, Esra; Tatlı, Ali Murat; Bahçeci, Aykut; Güven, Deniz Can; Caner, Burcu; Can, Alper; Gülmez, Ahmet; Karakaş, Yusuf; Yalçın, Bülent; Demirkazık, Ahmet; Bilici, Ahmet; Aydıner, Adnan; Yumuk, Perran Fulden; Şendur, Mehmet Ali Nahit (Springer, 2022)Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In ... -
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study
Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Kılıçkap, Sadettin; Atcı, Muhammed Mustafa; Kahraman, Seda; Keskinkılıç, Merve; Bilgetekin, İrem; Ayhan, Murat; Tural, Deniz; Eren, Önder; Akkoç Mustafayev, Fatma Nihan; Yaman, Şebnem; Tatlı, Ali Murat; Bayram, Ertuğrul; Kutlu, Yasin; Ertürk, İsmail; Özcan, Erkan; Gülmez, Ahmet; Korkmaz, Mustafa; Akagündüz, Baran; Erdem, Dilek; Akın Telli, Tuğba; Aksoy, Asude; Üskent, Necdet; İriağaç, Yakup; Köse Baytemür, Naziyet; Aydın, Dinçer; Sakalar, Teoman; Arak, Haci; Selçukbiricik, Fatih; Ergün, Yakup; Korkmaz, Taner; Ak, Naziye; Ünal, Çağlar; Akdeniz, Nadiye; Özgün, Mehmet Alpaslan; Öksüzoğlu, Berna; Yalçın, Bülent; Öztop, İlhan; Algın, Efnan; Sakin, Abdullah; Aydıner, Adnan; Yumuk, Perran Fulden; Şendur, Mehmet Ali Nahit (Future Medicine Ltd., 2022)Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell ...